1. Home
  2. OMDA vs HROW Comparison

OMDA vs HROW Comparison

Compare OMDA & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Omada Health Inc.

OMDA

Omada Health Inc.

N/A

Current Price

$14.44

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

HROW

Harrow Inc.

N/A

Current Price

$29.92

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OMDA
HROW
Founded
2011
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
2025
2008

Fundamental Metrics

Financial Performance
Metric
OMDA
HROW
Price
$14.44
$29.92
Analyst Decision
Buy
Strong Buy
Analyst Count
12
9
Target Price
$26.92
★ $62.25
AVG Volume (30 Days)
★ 1.2M
633.0K
Earning Date
11-05-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 94.27
71.43
EPS
★ 0.14
N/A
Revenue
★ $260,210,000.00
N/A
Revenue This Year
$30.17
$28.13
Revenue Next Year
$20.40
$56.02
P/E Ratio
$104.93
★ N/A
Revenue Growth
★ 53.24
N/A
52 Week Low
$10.28
$25.76
52 Week High
$25.45
$54.98

Technical Indicators

Market Signals
Indicator
OMDA
HROW
Relative Strength Index (RSI) 29.92 53.09
Support Level $14.01 $28.54
Resistance Level $15.11 $30.28
Average True Range (ATR) 0.92 1.79
MACD -0.38 0.37
Stochastic Oscillator 4.98 53.54

Price Performance

Historical Comparison
OMDA
HROW

About OMDA Omada Health Inc.

Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Share on Social Networks: